Replimune Group Financial Statements
NASDAQ: REPLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
19.07-0.16 (-0.83%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Replimune Group revenue and earnings
Replimune Group reported a net loss of $313.9 million, compared with a loss of $247.3 million a year earlier. Diluted earnings per share came in at -$3.38.
Summary generated from market data by MetaCap's automated system. Methodology
Replimune Group income statement (annual)
| Fiscal year (USD) | FY 20262026-03-31 | FY 20252025-03-31 | FY 20242024-03-31 | FY 20232023-03-31 | FY 20222022-03-31 | FY 20212021-03-31 | FY 20192020-03-31 | FY 20192019-03-31 | FY 20182018-03-31 | FY 20172017-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 319.92M | 261.63M | 234.77M | 177.08M | 118.31M | 79.95M | 56.20M | 30.95M | 19.23M | 9.65M |
| Research & Development | 221.18M | 189.45M | 174.96M | 126.53M | 79.55M | 56.75M | 38.76M | 22.17M | 13.52M | 6.94M |
| Selling, General & Admin | 98.73M | 72.18M | — | — | — | — | — | — | — | — |
| Operating Income | -319.92M | -261.63M | -234.77M | -177.08M | -118.31M | -79.95M | -56.20M | -30.95M | -19.23M | -9.65M |
| Interest Expense | 6.80M | 5.78M | 4.50M | 1.96M | 0 | 818.00K | 734.00K | — | — | — |
| Other Income (Expense) | 5.43M | 14.80M | 19.39M | 3.08M | 278.00K | -915.00K | 3.57M | 112.00K | -473.00K | 1.94M |
| Pretax Income | -314.49M | -246.83M | -215.39M | -174.00M | -118.04M | -80.87M | -52.63M | -30.83M | -19.70M | -7.70M |
| Income Tax | -551.00K | 468.00K | 408.00K | 288.00K | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -313.94M | -247.30M | -215.79M | -174.28M | -118.04M | -80.87M | -52.63M | -30.83M | -19.70M | -7.70M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -3.38 | -3.07 | -3.24 | -2.99 | -2.26 | -1.75 | -1.54 | -1.33 | -3.96 | -1.55 |
| EPS (Diluted) | -3.38 | -3.07 | -3.24 | -2.99 | -2.26 | -1.75 | -1.54 | -1.33 | -3.96 | -1.55 |
| Shares Outstanding (Basic) | 92.80M | 80.56M | 66.57M | 58.21M | 52.21M | 46.25M | 34.26M | 23.20M | 4.98M | 4.97M |
| Shares Outstanding (Diluted) | 92.80M | 80.56M | 66.57M | 58.21M | 52.21M | 46.25M | 34.26M | 23.20M | 4.98M | 4.97M |
| EBITDA | -316.59M | -258.13M | -232.12M | -174.63M | -116.17M | -78.24M | -55.66M | -30.80M | -19.12M | -9.53M |
This table shows 10 annual periods of Replimune Group's income statement, from FY 2026 back to FY 2017, across 14 line items including operating expenses, research & development, selling, general & admin. Values in USD; B = billions, M = millions. Fiscal periods follow REPL's reporting calendar. What is a income statement?